Full data set of Oncopeptides phase 2 HORIZON study in multiple myeloma published in the Journal of Clinical Oncology
Triple Class Refractory (n=119)
Extra Medullary Disease (n=55)
Overall Response Rate (ORR)
4.2 months
5.5 months
8.5 months
For more information, please contact:
Klaas Bakker, MD, PhD, Chief Medical Officer, Oncopeptides
Mail: klaas.bakker@oncopeptides.com
E-mail: rein.piir@oncopeptides.com
Cell phone: +46 70 853 72 92
The information in this press release was submitted for publication on December 9, 2020 at 22:00 (CET).
About melflufen
Melflufen (INN melphalan flufenamide) is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately hydrolyzed by peptidases to release an entrapped hydrophilic alkylator payload. Aminopeptidases are overexpressed in tumor cells and are even more pronoun